Astellas and Immunomic Therapeutics, Inc. have entered into an exclusive license agreement for Japan to develop and commercialize JRC2-LAMP-vax, Immunomic’s vaccine to treat allergies induced by Japanese red cedar pollen.   Astellas is responsible for developing and commercializing JRC2-LAMP-vax in Japan. Immunomic will receive $15 million upfront and as much as $55 million in development and regulatory milestones, as well as royalties on sales. Astellas will fund development costs and has...